120-Day Business Development Plan

Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla ® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data,…